Company Has FDA Fast Track Designation for Combination of REQORSA and Keytruda
Investor presentation to highlight the Company’s gene therapies for cancer and diabetes
A new study published in Cancer Gene Therapy by independent researchers outlines REQORSA as a promising therapeutic candidate for combinational therapy in cancer
Company has FDA Fast Track Designation for combination of REQORSA and Tagrisso
Designed and Secured by Barsec